Jobs
-
According to a newspaper report, Novartis has confirmed that it will retain its respiratory disease research center in Horsham, UK, with 440 employees. The company will sell a portion of the site and plans to… Read more . . .
-
GE Capital Healthcare Financial Services has announced today that it is providing $7.5 million in financing to Trimel Pharmaceuticals for Phase 2 and 3 clinical development of several OINDPs. Trimel’s pipeline includes asthma and allergic… Read more . . .
-
Lightlake Therapeutics has announced what it called “very encouraging preliminary results” from a Phase 2 clinical trial of its naloxone nasal spray for the treatment of binge eating disorder. According to the company, the randomized,… Read more . . .
-
Israeli biopharmaceutical company Kamada will receive milestone payments of $60 million as part of a 12-year distribution agreement with Chiesi Farmaceutici for Kamada’s inhaled alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency (AATD-IH). Chiesi… Read more . . .
-
According to Insmed, the US Patent and Trademark Office has issued the company a second composition of matter patent for Arikace liposomal amikacin for inhalation, US Patent No. 8,226,975. Insmed is developing the product for… Read more . . .
-
Inhaled drug company Alexza Pharmaceuticals has announced the promotions of four executives. The company has promoted James V. Cassella to Executive VP, Research and Development and Chief Scientific Officer; Darl Moreland to Senior VP, Quality;… Read more . . .
-
Melbourn Scientific has added a Proveris SprayVIEW system and Vereo actuator, making the contract research organization the first in Europe to offer cGMP spray pattern and plume geometry measurements required for nasal spray and MDI… Read more . . .
-
Aptar Pharma has announced that the Zetonna nasal aerosol device recently launched in the US includes a customized Aptar Landmark dose indicator, the result of a six-year collaboration with Sunovion. Zetonna is delivered by a… Read more . . .
-
In the wake of the EMA’s recent recommendation against use the use of calcitonin nasal sprays due to an increased risk of cancer, Health Canada says that it is also evaluating the risks of calcitonin… Read more . . .
-
The FDA has approved Watson Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for a generic version of Pulmicort Respules. The budesonide inhalation suspension 0.25mg/2mL and 0.5mg/2mL ampules are the subject of an ongoing patent dispute with… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.